



# Indicator Analysis 2022

## Annual Report of the Certified Neuro-oncology Cancer Centres

Audit year 2021 / Indicator year 2020

**FAO-Z360 MNOZ**


**Neuro-Oncology Centre Example Town**

## Table of Contents

Introduction .....	3
General information .....	3
Status of the certification system for Neuro-oncology Cancer Centres 2021 .....	5
Clinical sites taken into account .....	6
Tumour documentation systems at the Centres' clinical sites.....	7
Analysis of basic data .....	8
Analysis of indicators .....	11
Indicator No. 1a: Number of primary cases .....	11
Indicator No. 1b: Patient with recurrence/progress.....	12
Indicator No. 1c: Cerebral metastasis.....	13
Indicator No. 2a: Interdisciplinary case discussions.....	14
Indicator No. 2b: Pretherapeutic interdisciplinary case discussions.....	15
Indicator No. 3: Psycho-oncological care .....	16
Indicator No. 4: Counselling social services .....	17
Indicator No. 5: Study participation.....	18
Indicator No. 6a: Surgical primary cases .....	19
Indicator No. 6b: Biopsy.....	20
Indicator No. 6c: Ratio biopsies/resections.....	21
Indicator No. 7a: Revision surgeries .....	22
Indicator No. 7b: Clinically symptomatic secondary bleeding.....	23
Indicator No. 8: Post-surgical wound infections .....	24
Indicator No. 9: Assessment palliative symptoms.....	25
Imprint .....	26

## General information

	Indicator definition	All clinical sites 2020		
		Median	Range	Patients total
Numerator	Primary cases (elective patients; pre-intervention, emergency patients; post-intervention) who were presented in the tumour board	164*	61 - 604	10032
Denominator	Primary cases (= Indicator 1a)	178*	106 - 618	10810
Rate	Target value $\geq 95\%$	96,86%	34,46% - 100%	92,80%**



### Basic information for indicators:

The definition of the **numerator**, **denominator** and the **target value** are taken from the data sheet.

The **median** for numerator and denominator does not refer to an existing center but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

**Range** specifies the value range for the numerator, denominator and ratio of all centers.


The column **Total Patients** displays the total of all patients treated according to the indicator and the corresponding quota.

### Diagram:

The x-axis indicates the number of centres and the y-axis represents the values in percent or number (e.g. primary cases). The target value is depicted as a green horizontal line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.




## General information



### Cohort development:

The **cohort development** in the years **2016**, **2017**, **2018**, **2019** and **2020** is presented in a boxplot diagram.



### Boxplot:

The x-axis represents the number of centres, the y-axis represents the range of values in percent or a number (e.g. primary cases). The target is shown as a green horizontal line. The median, also shown as a green horizontal line, divides the entire group into two equal halves.

## Status of the certification system for Neuro-oncology Cancer Centres 2021

	31.12.2021	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016
Ongoing certification procedures	3	5	2	2	5	8
Certified Centres	53	46	42	38	32	26
Certified clinical sites	54	47	43	39	33	27
Neuro-oncology Centres with 1 clinical site	52	45	41	37	31	25
2 clinical sites	1	1	1	1	1	1
3 clinical sites	0	0	0	0	0	0
4 clinical sites	0	0	0	0	0	0

## Clinical sites taken into account

	31.12.2021	31.12.2020	31.12.2019	31.12.2018	31.12.2017	31.12.2016
Clinical sites included in the Annual Report	51	44	40	38	30	24
equivalent to	94,4%	93,6%	93,0%	97,4%	90,9%	88,9%
Primary cases total*	10.810	9.914	9.254	8.820	7.219	5.067
Primary cases per clinical site (mean)*	211,9	225,3	231,4	232,1	240,6	211,1
Primary cases per clinical site (median)*	178	184,5	201,5	192,5	214	202,5


\*The figures are based on the clinical sites listed in the Annual Report.

This annual report looks at the neuro-oncological Centers certified in the certification system of the German Cancer Society. The basis for the diagrams in the annual report is the data sheet.

The annual report includes 51 of the 54 certified Center locations. Excluded are 3 sites that were certified for the first time in 2021 (data mapping of the complete calendar year is not mandatory for initial certifications). All 54 sites treated 11,163 primary neuro-oncology cases. A current overview of all certified sites is available at [www.oncomap.de](http://www.oncomap.de)

The indicators published here relate to the indicator year 2020 and provide the basis for the audits conducted in 2021.

## Tumour documentation systems in the Centre's clinical sites




Andere = Other  
Eigenentwicklung = Intrinsic development  
Tumorzentrum = Tumour centre

Legend:	
Other	Systems that are only used at one location at a time

The information on the tumour documentation system was taken from the data sheet (Basic Data Sheet). It is not possible to use several systems. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumor documentation system.

## Basic data – Stage distribution primary cases of neuro-oncological tumors




	Benign neoplasms (ICD-O-3 Morphology: .../0)				Malignant neoplasms (ICD-O-3 Morphology: .../3)				Uncertain behaviour (ICD-O-3 Morphology: .../1)				Total
	C70	C71	C72	C75	C70	C71	C72	C75	C70	C71	C72	C75	
Non-surgical	727 (22,04%)	69 (23,08%)	251 (24,78%)	161 (12,81%)	5 (10,00%)	927 (24,58%)	44 (27,33%)	9 (47,37%)	4 (1,05%)	52 (13,87%)	9 (8,57%)	12 (15,19%)	2.270
Surgical	2.571 (77,96%)	230 (76,92%)	762 (75,22%)	1.096 (87,19%)	45 (90,00%)	2.845 (75,42%)	117 (72,67%)	10 (52,63%)	378 (98,95%)	323 (86,13%)	96 (91,43%)	67 (84,81%)	8.540
<b>Primary cases total</b>	3.298 (100%)	299 (100%)	1.013 (100%)	1.257 (100%)	50 (100%)	3.772 (100%)	161 (100%)	19 (100%)	382 (100%)	375 (100%)	105 (100%)	79 (100%)	10.810

**C70:** neoplasm of meninges; **C71:** neoplasm of brain; **C72:** neoplasm of medulla and cerebral nerves; **C75:** Other endocrine glands and related structures in line with ICD-O-3 topography






## Basic data - Center cases neuro-oncological tumors



Primary cases	Recurrences/Progressions	Centre cases
10.810 (76,07%)	3.401 (23,93%)	14.211 (100%)


## Basic data - Surgical expertise (number of resections - number of biopsies)




Operative expertise - Number of resections	Operative expertise - Number of biopsies
12.504 (86,22%)	1.999 (13,78%)

\*Operative expertise: Resections or biopsies in primary cases, patients with recurrences/progressions and metastases in the calendar year are counted, regardless of primary case status.

# 1a. Number of primary cases



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Number	Primary cases def. in line with 1.2.1	262	267	318	291	300
	Target value ≥ 100					




	2016	2017	2018	2019	2020
Max	613,00	630,00	616,00	607,00	618,00
95 <sup>th</sup> percentile	444,25	448,35	436,70	434,00	403,50
75 <sup>th</sup> percentile	290,25	279,50	276,25	291,50	263,00
Median	214,00	192,50	201,50	184,50	178,00
25 <sup>th</sup> percentile	162,00	158,00	143,75	149,00	136,00
5 <sup>th</sup> percentile	118,15	118,65	132,85	115,75	117,50
Min	110,00	111,00	115,00	109,00	106,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	51	100,00%

**Comments:**

## 1b. Patients with recurrence/progression



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Number	Patients with recurrence/progression	k.A.	k.A.	k.A.	k.A.	129
	No target value					




	2016	2017	2018	2019	2020
Max	----	----	----	----	296,00
95 <sup>th</sup> percentile	----	----	----	----	175,00
75 <sup>th</sup> percentile	----	----	----	----	84,00
Median	----	----	----	----	47,00
25 <sup>th</sup> percentile	----	----	----	----	27,00
5 <sup>th</sup> percentile	----	----	----	----	9,00
Min	----	----	----	----	2,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	----	----

Comments:

### 1c. Cerebral metastasis



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Number	Patients with cerebral metastasis who received care at the NOZ	k.A.	k.A.	k.A.	k.A.	120
	No target value					




	2016	2017	2018	2019	2020
Max	----	----	----	----	336,00
95 <sup>th</sup> percentile	----	----	----	----	193,60
75 <sup>th</sup> percentile	----	----	----	----	104,00
Median	----	----	----	----	67,00
25 <sup>th</sup> percentile	----	----	----	----	41,00
5 <sup>th</sup> percentile	----	----	----	----	21,60
Min	----	----	----	----	1,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
37	72,55%	----	----

Comments:

## 2a. Interdisciplinary case discussions



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Primary cases (elective patients: pre-intervention. emergency patients: post-intervention) who were presented in the tumour board	259	258	308	287	286
Denominator	Primary cases (= Indicator 1a)	262	267	318	291	300
Rate	Target value ≥ 95%	98,85%	96,63%	96,86%	98,63%	95,33%




	2016	2017	2018	2019	2020
Max	100%	100%	100%	100%	100%
95 <sup>th</sup> percentile	99,55%	100%	100%	100%	99,73%
75 <sup>th</sup> percentile	98,35%	98,77%	98,71%	98,35%	98,48%
Median	96,36%	96,95%	96,72%	96,81%	96,86%
25 <sup>th</sup> percentile	93,77%	91,32%	94,91%	95,67%	95,19%
5 <sup>th</sup> percentile	47,96%	57,56%	71,30%	68,52%	74,32%
Min	20,87%	22,52%	24,11%	39,36%	34,46%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	39	76,47%


Comments:

## 2b. Pretherapeutic interdisciplinary case discussions



Begründungspflicht = mandatory statement for reasons

	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Primary cases of the denominator that were preinterventionally presented in tumor board	k.A.	k.A.	k.A.	k.A.	157
Denominator	Primary cases (= Indicator 1a)	k.A.	k.A.	k.A.	k.A.	202
Rate	Mandatory statement for reasons*** <50% and >80%	k.A.	k.A.	k.A.	k.A.	77,72%




	2016	2017	2018	2019	2020
● Max	----	----	----	----	99,46%
95 <sup>th</sup> percentile	----	----	----	----	97,86%
75 <sup>th</sup> percentile	----	----	----	----	91,62%
Median	----	----	----	----	78,32%
25 <sup>th</sup> percentile	----	----	----	----	68,19%
5 <sup>th</sup> percentile	----	----	----	----	39,00%
● Min	----	----	----	----	30,59%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
35	68,63%	16	45,71%

Comments:


\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.

### 3. Psycho-oncological care



Begründungspflicht = mandatory statement for reasons

	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Primary cases who received psycho-oncological care in an inpatient or outpatient setting (consultation ≥ 25 min)	220	173	228	199	205
Denominator	Primary cases (= Indicator 1b) and patients with recurrence	285	286	355	353	429
Rate	Mandatory statement for reasons*** < 10% and >75%	77,19%	60,49%	64,23%	56,37%	47,79%



	2016	2017	2018	2019	2020
Max	77,19%	60,49%	64,23%	72,82%	66,37%
95 <sup>th</sup> percentile	54,36%	53,87%	52,44%	54,19%	48,21%
75 <sup>th</sup> percentile	31,00%	29,37%	29,70%	33,14%	34,68%
Median	18,24%	21,63%	18,46%	21,76%	26,21%
25 <sup>th</sup> percentile	13,03%	12,68%	13,06%	17,18%	15,84%
5 <sup>th</sup> percentile	2,26%	5,16%	7,09%	9,89%	8,51%
Min	1,52%	1,31%	4,27%	7,68%	6,45%


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	46	90,20%

Comments:

\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.




## 4. Counselling social services



Begründungspflicht = mandatory statement for reasons

	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Primary cases who received counselling by social services in an inpatient or outpatient setting	247	208	217	224	221
Denominator	Primary cases (= Indicator 1a) and patients with recurrence/progress (= Indicator 1b)	285	286	355	353	429
Rate	Mandatory statement for reasons*** < 50%	86,67%	72,73%	61,13%	63,46%	51,52%




	2016	2017	2018	2019	2020
Max	99,01%	99,04%	100%	94,95%	91,65%
95 <sup>th</sup> percentile	96,35%	91,51%	96,18%	83,80%	78,37%
75 <sup>th</sup> percentile	78,87%	71,95%	69,13%	63,62%	61,20%
Median	66,75%	61,47%	53,51%	51,96%	52,34%
25 <sup>th</sup> percentile	47,72%	47,74%	43,81%	42,93%	43,50%
5 <sup>th</sup> percentile	35,70%	32,92%	31,11%	30,65%	27,65%
Min	28,14%	22,26%	19,25%	29,10%	17,34%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	32	62,75%


Comments:

\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.

## 5. Study participation



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	All patients (malignant and benign) included in a study with an ethic vote	34	83	100	100	161
Denominator	Malignant primary cases	91	66	74	63	74
Rate	Target value $\geq$ 5%	37,36%	125,76%	135,14%	158,73%	217,57%




	2016	2017	2018	2019	2020
Max	601,06%	601,09%	787,88%	966,22%	567,74%
95 <sup>th</sup> percentile	288,98%	233,18%	232,51%	346,81%	350,23%
75 <sup>th</sup> percentile	46,20%	63,76%	74,11%	79,34%	67,31%
Median	26,87%	29,22%	34,13%	40,67%	42,52%
25 <sup>th</sup> percentile	9,62%	14,95%	17,39%	19,55%	15,78%
5 <sup>th</sup> percentile	6,44%	6,19%	8,51%	6,46%	4,67%
Min	5,61%	5,04%	3,39%	0,00%	1,56%


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	47	92,16%

Comments:

## 6a. Surgical primary cases



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Number	Surgical primary cases def. in line with 5.2.3.a	189	202	199	176	173
	Target value ≥ 60					




	2016	2017	2018	2019	2020
Max	605,00	626,00	610,00	601,00	613,00
95 <sup>th</sup> percentile	368,75	356,75	375,70	344,85	341,50
75 <sup>th</sup> percentile	241,00	223,50	233,75	208,25	192,50
Median	171,50	165,00	147,00	140,00	130,00
25 <sup>th</sup> percentile	129,00	118,00	114,25	112,00	108,00
5 <sup>th</sup> percentile	100,35	89,00	85,00	84,30	74,50
Min	87,00	74,00	67,00	72,00	65,00


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	51	100,00%

Comments:

## 6b. Biopsy



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Number	Biopsies def. in line with 5.2.3b	28	31	46	39	35
	No target value					




	2016	2017	2018	2019	2020
Max	125,00	135,00	136,00	140,00	85,00
95 <sup>th</sup> percentile	86,80	91,90	79,00	93,80	56,50
75 <sup>th</sup> percentile	37,50	36,00	37,25	41,25	26,00
Median	27,50	27,00	23,50	22,00	19,00
25 <sup>th</sup> percentile	16,50	15,25	15,75	14,00	14,00
5 <sup>th</sup> percentile	11,45	6,85	5,00	6,30	11,50
Min	10,00	6,00	4,00	3,00	11,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	-----	-----


Comments:

## 6c. Ratio biopsies/resections



Begründungspflicht = mandatory statement for reasons

	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Biopsies (= Indicator 6b)	k.A.	k.A.	k.A.	k.A.	35
Denominator	Surgical primary cases (= Indicator 6a)	k.A.	k.A.	k.A.	k.A.	173
Rate	Mandatory statement for reasons*** <10% and >25%	k.A.	k.A.	k.A.	k.A.	20,23%




	2016	2017	2018	2019	2020
Max	----	----	----	----	54,65%
95 <sup>th</sup> percentile	----	----	----	----	35,07%
75 <sup>th</sup> percentile	----	----	----	----	19,95%
Median	----	----	----	----	13,25%
25 <sup>th</sup> percentile	----	----	----	----	10,63%
5 <sup>th</sup> percentile	----	----	----	----	7,41%
Min	----	----	----	----	3,98%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	35	68,63%

**Comments:**


\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.

## 7a. Revision surgeries



Begründungspflicht = mandatory statement for reasons

	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Revision surgeries as a consequence of post-surgical complications within 30d after surgery (for surgical primary cases)	11	13	4	2	3
Denominator	Surgical primary cases (= Indicator 6a)	189	202	199	176	173
Rate	Mandatory statement for reasons*** < 1% and >10%	5,82%	6,44%	2,01%	1,14%	1,73%




	2016	2017	2018	2019	2020
Max	9,70%	10,81%	9,20%	9,85%	12,35%
95 <sup>th</sup> percentile	8,94%	9,59%	9,03%	9,38%	10,74%
75 <sup>th</sup> percentile	6,79%	6,45%	6,88%	7,29%	8,55%
Median	5,09%	5,51%	5,09%	5,45%	5,98%
25 <sup>th</sup> percentile	3,64%	3,57%	3,39%	4,19%	4,34%
5 <sup>th</sup> percentile	2,26%	2,28%	2,01%	1,18%	2,13%
Min	0,85%	2,03%	1,83%	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	45	88,24%


**Comments:**

\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.

## 7b. Clinically symptomatic secondary bleeding



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Surgical primary cases with clinically symptomatic secondary bleeding (= new onset or worsening of an existing neurological disorder)	5	3	6	6	2
Denominator	Surgical primary cases (= Indicator 6a)	218	186	170	195	162
Rate	Mandatory statement for reasons*** < 1% and >10%	2,29%	1,61%	3,53%	3,08%	1,23%




	2016	2017	2018	2019	2020
Max	6,15%	8,85%	7,60%	7,58%	7,41%
95 <sup>th</sup> percentile	5,56%	7,32%	6,84%	5,93%	6,18%
75 <sup>th</sup> percentile	3,68%	3,78%	3,87%	3,90%	4,29%
Median	2,54%	1,88%	2,71%	1,96%	2,31%
25 <sup>th</sup> percentile	1,54%	1,28%	1,43%	1,38%	1,33%
5 <sup>th</sup> percentile	0,35%	0,43%	0,00%	0,11%	0,00%
Min	0,00%	0,00%	0,00%	0,00%	0,00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	41	80,39%


### Comments:

\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.

## 8. Post-surgical wound infections



	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Surgical primary cases with post-surgical meningitis confirmed by laboratory tests and/or a wound infection requiring surgical revision within 30d of surgery	6	4	2	3	3
Denominator	Surgical primary cases (= Indicator 6a)	218	186	170	195	162
Rate	Mandatory statement for reasons*** < 1% and >10%	2,75%	2,15%	1,18%	1,54%	1,85%



	2016	2017	2018	2019	2020
Max	6,48%	8,02%	5,88%	4,64%	7,69%
95 <sup>th</sup> percentile	5,47%	5,47%	3,88%	4,19%	4,68%
75 <sup>th</sup> percentile	3,03%	2,54%	2,41%	2,96%	3,00%
Median	1,85%	1,51%	1,47%	1,52%	2,27%
25 <sup>th</sup> percentile	0,86%	0,86%	0,82%	0,82%	1,18%
5 <sup>th</sup> percentile	0,00%	0,28%	0,00%	0,00%	0,29%
Min	0,00%	0,00%	0,00%	0,00%	0,00%


Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
51	100,00%	40	78,43%

### Comments:

\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.




## 9. Assessment palliative symptoms



Begründungspflicht = mandatory statement for reasons

	Indicator definition	FAO-Z360 MNOZ				
		2016	2017	2018	2019	2020
Numerator	Patients with symptom recording using MIDOS or IPOS	k.A.	k.A.	k.A.	k.A.	15
Denominator	Patients with ICD-O topography C71 and ICD-O morphology /03	k.A.	k.A.	k.A.	k.A.	72
Rate	Mandatory statement for reasons*** <60%	k.A.	k.A.	k.A.	k.A.	20,83%



	2016	2017	2018	2019	2020
● Max	----	----	----	----	100%
95 <sup>th</sup> percentile	----	----	----	----	100%
75 <sup>th</sup> percentile	----	----	----	----	32,46%
Median	----	----	----	----	1,30%
25 <sup>th</sup> percentile	----	----	----	----	0,00%
5 <sup>th</sup> percentile	----	----	----	----	0,00%
● Min	----	----	----	----	0,00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
17	33,33%	3	17,65%

Comments:

\* In the case of values outside the plausibility limit(s), the centers are required to provide justification.

# WISSEN AUS ERSTER HAND (FIRST-HAND KNOWLEDGE)



Find out more on [www.krebsgesellschaft.de](http://www.krebsgesellschaft.de)

## Authors

German Cancer Society (DKG)  
Certification Committee for Neuro-oncology Cancer Centres  
Uwe Schlegel, Spokesman Certification Committee  
Walter Stummer, Deputy Spokesman Certification Committee  
Simone Wesselmann, German Cancer Society (DKG)  
Johannes Rückher, German Cancer Society (DKG)  
Martin Utzig, German Cancer Society (DKG)  
Ellen Griesshammer, German Cancer Society (DKG)  
Viktoria Sonnentag, OnkoZert GmbH  
Florina Dudu, OnkoZert GmbH

## Imprint

Publisher and responsible for content:  
Deutsche Krebsgesellschaft (DKG)  
Kuno-Fischer-Straße 8  
14057 Berlin  
Tel.: +49 (030) 322 93 29 0  
Vereinsregister Amtsgericht Charlottenburg,  
Vereinsregister-Nr.: VR 27661 B  
V.i.S.d.P.: Dr. Johannes Bruns

in cooperation with:  
OnkoZert, Neu-Ulm  
[www.onkozert.de](http://www.onkozert.de)

Based on the version of the General Annual  
Report, Version e-A1-de; Stand 07.03.2022